HDAC2 and chronic obstructive pulmonary disease: Our previous studies have shown that carbocisteine (S-CMC), an anti-oxidant agent extensively used as adjunctive therapy in the treatment of chronic obstructive pulmonary disease (COPD), could reverse the down-regulation of HDAC2 induced by oxidative stress and enhance the sensitivity of human alveolar epithelial cells to glucocorticoid (GC) treatment (Song et al., 2015).